News & Updates

Timing of antihypertensive medication intake, be it in the morning or evening, does not appear to affect the risk of cardiovascular death or hospitalization for non-fatal myocardial infarction (MI) or non-fatal stroke, according to results of the TIME trial presented at ESC 2022.

The selective β3-AR agonist mirabegron appears to confer benefits for both overactive bladder (OAB) symptoms and erectile dysfunction (ED) in some patients without compromising safety, as reported in a study.

Treatment with sotrovimab does not appear to confer protection against severe forms of COVID-19 in a setting dominated by the Omicron BA.2 subvariant, a study has found.

In type 2 diabetes (T2D) patients with constipation, treatment with elobixibat alleviates constipation while improving glucose metabolism and lowering serum low-density lipoprotein cholesterol (LDL-C) and arachidonic acid (AA) levels, according to the results of a single-arm pilot study.

The use of minocycline as add-on to antidepressant treatment in patients with treatment-resistant depression is safe but falls short of efficacy thresholds relative to placebo, as shown in a study.

Many infectious disease-related hospital admissions in patients with inflammatory bowel disease may have been prevented by immunization, suggests a study.

Applying roflumilast cream topically once-a-day helps clear plaque psoriasis in 8 weeks, according to pooled data from the phase III DERMIS-1 and DERMIS-2 trials.

Serum levels of adalimumab at week 2 is associated with short-term clinical remission in patients with inflammatory bowel disease (IBD), a study has shown.

Rocatinlimab improved disease severity in patients with moderate-to-severe head and neck atopic dermatitis (H&N AD), a post hoc analysis of a phase IIb trial has shown.